The following is a summary of “Nomogram for predicting proliferative lupus nephritis in patients with low-level proteinuria,” ...

A recent nationwide population-based cohort study has shed light on the significant relationship between proteinuria and the ...

IgA nephropathy (IgAN) is an autoimmune kidney disease driven by immune cells that express a protein called CD38 on their ...

Genetically modified pig kidneys begin trials for 50 U.S. kidney failure patients FDA launches clinical trials for organ ...

Delta4 receives European patents for two compounds as candidate treatments for focal segmental glomerulosclerosis: Vienna, Austria Monday, February 3, 2025, 18:00 Hrs [IST] Delta4 ...

February is observed as American Heart Month, a period dedicated to raising awareness about heart health. The first American Heart ...

Renalys Pharma completes patient enrollment in registrational phase III trial of sparsentan for IgA nephropathy in Japan: Tokyo, Japan Friday, January 31, 2025, 18:00 Hrs [IST] Re ...

United Therapeutics Corporation , a public benefit corporation, today announced that the U.S. Food and Drug Administration (FDA) has cleared its Investigational New Drug application (IND) to initiate ...

It’s the quarterly season again as the ASX market announcements page becomes increasingly flooded with news updates.

In studies, Fabhalta proved that it could reduce proteinuria for C3G patients, a marker for delaying progression to kidney failure. So far, there are no approved treatments for the ultra-rare ...

A recent study from Johns Hopkins University has raised concerns about rosuvastatin, a widely used drug for lowering ...

Net sales grew +12% (cc 1, +11% USD) with core operating income 1 up +22% (cc, +19% USD) Sales growth driven by continued st ...